Chhattisgarh Flags Substandard Drugs in Quality Control Drive, Vows Strict Action

Nationwide Drug Policing Nationwide Drug Policing

Posted by TGANB-Admin on 2025-06-24 08:46:40 |

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 1

---

Raipur, Chhattisgarh, June 24, 2025 – Three drug samples collected from various districts across Chhattisgarh have been declared substandard following rigorous inspections by the state's Food and Drug Administration (FDA) and subsequent laboratory testing. This revelation comes as part of an intensified, ongoing drive aimed at ensuring the availability of quality medicines for public health.

Departmental sources confirmed that a total of 34 drug samples were gathered from key districts including Raipur, Bilaspur, Durg, Sakti, Rajnandgaon, Kondagaon, and Surajpur. These samples were meticulously sent to the State Drug Testing Laboratory in Raipur. After comprehensive testing conducted in May 2025, three specific medicines failed to meet the required quality standards.

The substandard drugs identified are: Vildamed Tablet (Batch No. VGT 242068A), manufactured by Vrindavan Global, Solan, Himachal Pradesh; Rifliwe M Tablet (Batch No. HG 24080598), manufactured by I Heal Pharmaceuticals, Baddi, Himachal Pradesh; and Donlocare DS Suspension (Batch No. DCN-002), manufactured by Quixotic Pharma, Mohali, Punjab. A departmental spokesperson confirmed that action is being initiated against the concerned manufacturers and distributors in accordance with existing regulations.

State Health Minister Shyam Bihari Jaiswal unequivocally stated, "There will be no compromise with public health. Strict action will be taken against those selling or distributing substandard medicines. Our government is committed to ensuring high-quality healthcare services in the state. All drug retailers have been instructed to sell only recognised and certified medicines."

In a related development, teams of drug inspectors are conducting continuous raids on medical stores across Chhattisgarh, specifically targeting the misuse and illicit sale of narcotic drugs. Furthermore, work is progressing rapidly to equip all medical establishments with CCTV cameras, a directive from the government aimed at enhancing surveillance and accountability. The FDA has urged the public to remain vigilant, check the quality and expiry dates of medicines, and report any suspicious drugs to the department, reinforcing the collaborative effort required to maintain public safety.

Go!